Breast Diseases and Myoma Uteri Co-Occurness

Yıl 2018, Cilt: 8 Sayı: 3, 183 - 189, 01.12.2018

Funda Dinç Elibol Sezen Bozkurt Köseoğlu

Öz

Aim: To evaluate the association between fibrocystic changes of
the breast and myoma uteri of which have hormonal factors in their
etiology.
Material and Method: Between January 2017 to March 2017 a
total of 665 consecutive women were retrospectively evaluated.
One hundred and four patients having myoma uteri and 84 patients not having myoma uteri proved with imaging techniques,
were included in the study. Mammographic breast density, and
also whether there were mass, microcalcification, axillary lymphadenopathy or not, and mammographic BI-RADS results were
enrolled. Besides, breast type, solid lesions, cysts, multiple cysts,
ductal ectasia in ultrasonography and sonographic BI-RADS results were recorded. If it is available, the biopsy results were
noted.
Results: Mean age of myoma uteri group was 48.6±6.1 and control group was 50.0±8.7 and there was consistency in respect to
ages. There was no significant difference in breast density, mass,
microcalcification, ductal ectasia, and malignant lesions between
the study and control group. Statistically, a significant difference
was found in breast cysts between study (% 72.5) and control (%
51.9) group (p=0.008).
Conclusion: Fibrocystic changes are more common in myoma
uteri. It might be helpful in clinical practice to keep in mind this
result in management of myoma uteri patients.

Anahtar Kelimeler

ibrocystic changes; breast cycts; myoma uteri

Meme Hastalıkları Miyoma Uteri Birlikteliği

Öz

Amaç:
Etiyolojisinde  hormonal faktörlerin
suçlandığı memenin fibrokistik değişiklikleri ve miyoma uteri birlikteliğinin
değerlendirilmesi amaçlanmıştır.

Materyal ve Metod: Ocak 2017-Mart 2017 tarihleri arasında toplam 655 ardışık
kadın hasta geriye dönük tarandı. Görüntüleme bulguları ile miyoma uterisi olan
104 ve olmayan 84 hasta çalışmaya dahil edildi. Mamografide meme dansitesi ve
ayrıca kitle, mikrokalsifikasyon, aksiller lenfadenopati bulunup bulunmaması,
mamografi raporunun BI-RADS sonucu kaydedildi. Ayrıca hastaya ait meme
ultrasonografisinde meme tipi, ultrasonografide solid lezyon, kist, multipl
kist, duktal ektazi bulunup bulunmadığı ve BI-RADS sonucu değerlendirildi. Eğer
mevcut ise biyopsi sonuçları da kaydedildi.

Bulgular:
Miyoma uteri grubunda yaş ortalaması 48.6±6.1, kontrol grubunda 50.0±8.7 olup
gruplar yaş bakımından uyumlu bulunmuştur. Çalışma ve kontrol grubunda meme
dansiteleri, solid kitle, mikrokalsifikasyon, duktal ektazi vemalign lezyon
sıklığı, açısından fark bulunmazken, kistler myoma uteri grubunda (%72.5)
istatisitiksel olarak kontrol grubuna göre (%51.9) daha sık olarak bulunmuştur
(p=0.008).

Sonuç: Miyoma
uteride fibrokistik değişiklikler daha sık görülmektedir. Bu sonucun klinik
pratikte miyoma uterili hastaların yönetiminde dikkate alınması faydalı
olacaktır.

Anahtar Kelimeler

fibrokistik değişiklikler, meme kistleri, miyoma uteri

Kaynakça

• 1. Wu C1, Ray RM, Lin MG, Gao DL, Horner NK, Nelson ZC et al. A case-control study of risk factors for fibrocystic breast conditions: Shanghai Nutrition and Breast Disease Study, China, 1995-2000. Am J Epidemiol 2004; 160(10):945–60.
• 2. Mannello F, Tonti GAM, Papa S. Human gross cyst breast disease and cystic fluid: bio-molecular, morphological, and clinical studies. Breast Cancer Res Treat 2006;97(2):115–29.
• 3. Talaei A, Moradi A, Rafiei F. The evaluation of the effect of metformin on breast fibrocystic disease. Breast Dis 2017;37(2):49–53.
• 4. Gadducci A, Guerrieri ME, Genazzani AR. Benign breast diseases, contraception and hormone replacement therapy. Minerva Ginecol 2012 ;64(1):67–74.
• 5. Azam S, Lange T, Huynh S, Aro AR, von Euler-Chelpin M, Vejborg I, et al. Hormone replacement therapy, mammographic density, and breast cancer risk: a cohort study. Cancer Causes Control 2018 Apr 18 (doi: 10.1007/s10552-018-1033-0)
• 6. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 2007;87(4):725–36.
• 7. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990;94(4):435–8.
• 8. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003;111(8):1037–54.
• 9. Yenen MC, Dede M, Goktolga U, Kuçuk T, Pabuçcu R. Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy. Climacteric 2003;6(2):146–50.
• 10. Mellissa YongCharlotte AtkinsonKatherine M. NewtonErin J. Aiello BowlesFrank Z. Stanczyk et al. Associations between endogenous sex hormone levels and mammographic and bone densities in premenopausal women. Cancer Causes Control 2009;20(7):1039–53.
• 11. Bertrand KA, Eliassen AH, Hankinson SE, Rosner BA, Tamimi RM. Circulating Hormones and Mammographic Density in Premenopausal Women. Horm Cancer 2018;9(2):117–27.
• 12. Anil C, Guney T, Gursoy A. The prevalence of benign breast diseases in patients with nodular goiter and Hashimoto’s thyroiditis. J Endocrinol Invest 2015;38(9):971–5.
• 13. Giustarini, E., Pinchera, A., Fierabracci, P., Roncella, M., Fustaino, L., Mammoli, C., et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. European journal of endocrinology, 154(5), 645-649.
• 14. Ozkaya, E., Cakir, E., Cinar, M., Kara, F., Baser, E., Cakir, C.,et al. (2012). Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?. Gynecological Endocrinology, 28(6), 468-471.
• 15. Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. Am J Obstet Gynecol 1986;154(1):161–79.
• 16. Habor V, Habor A, Copotoiu C, Panţîru A. Fibrocystic breast disease--breast cancer sequence. Chirurgia 2010;105(2):191–4.
• 17. Meisner ALW, Houman Fekrazad M, Royce ME. Breast Disease: Benign and Malignant. Med Clin North Am 2008;92(5):1115–41.
• 18. Audisio T, Crespo-Roca F, Giraudo P, Ramallo R. Fibroadenoma of the vulva- simultaneous with breast fibroadenomas and uterine myoma. J Low Genit Tract Dis. 2011;15(1):75-9.